Literature DB >> 22300992

Strategies for the management of rheumatoid arthritis.

W S Wilkie1, Philip Schwieterman.   

Abstract

Rheumatoid arthritis is a chronic, systemic inflammatory autoimmune disease that, untreated, can lead to permanent joint damage, decrease in quality of life, and disability. Health care professionals play a vital role in caring for patients with rheumatoid arthritis. The therapeutic possibilities in the management of rheumatoid arthritis have changed, with newer biologic therapies that target the inflammatory cascade seen in rheumatoid arthritis. As new treatments become increasingly available, it is important for health care professionals to stay informed. This article provides physicians with a review of biologic therapies currently used for the treatment of rheumatoid arthritis and describe how those therapies are used to manage rheumatoid arthritis. Copyright 2012, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300992     DOI: 10.3928/01477447-20120123-36

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  7 in total

Review 1.  [Update on kinase inhibitors].

Authors:  R Alten
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

2.  Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.

Authors:  Mohamed-Eslam F Mohamed; Heidi S Camp; Ping Jiang; Robert J Padley; Armen Asatryan; Ahmed A Othman
Journal:  Clin Pharmacokinet       Date:  2016-12       Impact factor: 6.447

Review 3.  Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

Review 4.  [Intracellular targets : current data on effectiveness and safety profile].

Authors:  R Alten
Journal:  Z Rheumatol       Date:  2013-11       Impact factor: 1.372

5.  Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.

Authors:  Mohamed-Eslam F Mohamed; Denise Beck; Heidi S Camp; Ahmed A Othman
Journal:  J Clin Pharmacol       Date:  2019-08-25       Impact factor: 3.126

Review 6.  Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Ying He; Angel Y S Wong; Esther W Chan; Wallis C Y Lau; Kenneth K C Man; Celine S L Chui; Alan J Worsley; Ian C K Wong
Journal:  BMC Musculoskelet Disord       Date:  2013-10-18       Impact factor: 2.362

Review 7.  Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.

Authors:  Ben Klünder; Mohamed-Eslam F Mohamed; Ahmed A Othman
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.